Avidicure
Seed Round in 2025
Avidicure is a cancer care company focused on enhancing immune system performance through innovative therapeutic approaches. The company is developing a novel class of antibodies known as AVC-Boosters, which are engineered to act as dual agonists. This multifunctional modality aims to deliver targeted and effective monotherapy, offering broad applicability in oncology. Currently operating in stealth mode, Avidicure is dedicated to pioneering advancements in cancer treatment that prioritize safety and efficacy.
Augustine Therapeutics
Series A in 2025
Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.
ATB Therapeutics
Series A in 2024
ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
Confo Therapeutics
Series B in 2024
Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.
Augustine Therapeutics
Series A in 2024
Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.
Biodol Therapeutics
Grant in 2024
Biodol Therapeutics SAS is a biotechnology company based in Clapiers, France, established in 2015. The company focuses on developing innovative compounds for the treatment of chronic pain, specifically targeting the Receptor Tyrosine Kinase (RTK) FLT3, which plays a critical role in triggering and sustaining chronic neuropathic pain. Biodol Therapeutics' research indicates that inhibiting FLT3 can enhance the effectiveness of opioids, potentially reducing their risk of addiction and contributing to solutions for the opioid crisis. By creating extracellular inhibitors of the FLT3 receptor, the company aims to alleviate pain hypersensitivity, allodynia, and spontaneous pain while preserving normal nervous system function. Through academic partnerships, Biodol Therapeutics continues to advance its understanding of pain mechanisms and develop its proprietary therapeutic approaches.
Flindr Therapeutics
Series A in 2024
Flindr Therapeutics, a private biotech company develops next-generation precision oncology treatments.
Protealis
Series B in 2024
Protealis specializes in the development of advanced seeds and seed technologies for legume crops, focusing on enhancing their adaptability to the European environment. The company aims to be a leading provider of germplasm for sustainable plant proteins in Europe. By integrating innovative breeding techniques and nitrogen fixation methods, Protealis seeks to maximize the potential of legume crops. Additionally, the company employs proprietary seed coatings to support farmers in addressing the protein deficit and to provide local sourcing solutions for an increasing number of producers in the meat and milk alternatives sector.
Tanai Therapeutics
Seed Round in 2023
Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.
Corteria Pharmaceuticals
Series A in 2023
Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.
Aphea.Bio
Series C in 2023
Aphea.Bio is a company focused on developing next-generation biopesticides and biostimulants derived from natural microorganisms. Its biopesticides serve as an alternative to conventional chemical pesticides, addressing the increasing pressure on synthetic chemical use in agriculture. Additionally, the company creates biostimulants that enhance crop growth by improving the uptake of nutrients from the soil. Aphea.Bio's products aim to sustainably increase crop yields and health, specifically targeting crops such as maize and wheat. By utilizing proprietary technologies, the company accelerates the discovery of innovative biocontrol and biostimulant solutions, enabling farmers to manage pests, diseases, and fertilizer application more effectively.
Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.
Sibylla Biotech
Series A in 2022
Sibylla Biotech S.R.L. is an Italian biotechnology company focused on the research and development of innovative solutions for drug design. The company specializes in producing small molecule folding interfering degraders (FIDs) that target various therapeutic areas. Sibylla Biotech employs advanced patent-based software that utilizes algorithms and drug design protocols to enhance drug discovery processes. By implementing original reaction path sampling and data reduction techniques, the software aims to streamline the development of treatments for incurable diseases. In addition to its product development, Sibylla Biotech offers consultancy services in biotechnology and drug development, supporting medical practitioners in rationalizing their research efforts. The company is headquartered in Italy.
AstriVax
Seed Round in 2022
AstriVax is a biotechnology company focused on developing innovative vaccines that address significant challenges in the field of vaccinology. The company aims to achieve initial clinical validation of its platform technology, which is designed to create a diverse pipeline of vaccines. AstriVax's vaccine candidates are engineered to minimize cold chain requirements, making them more accessible and easier to distribute. Additionally, these vaccines are intended to provide broad and long-lasting protection against a variety of viruses and pathogens, thereby enhancing treatment options within the healthcare sector.
Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.
Corteria Pharmaceuticals
Seed Round in 2021
Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.
Coave Therapeutics
Series B in 2021
Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.
Muna Therapeutics
Series A in 2021
Muna Therapeutics is a private biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying innovative medicines that preserve cognitive functions and enhance resilience in individuals affected by these conditions. By prioritizing the development of suitable therapeutics, Muna Therapeutics aims to improve recovery outcomes for patients suffering from neurodegenerative diseases.
Protealis
Series A in 2021
Protealis specializes in the development of advanced seeds and seed technologies for legume crops, focusing on enhancing their adaptability to the European environment. The company aims to be a leading provider of germplasm for sustainable plant proteins in Europe. By integrating innovative breeding techniques and nitrogen fixation methods, Protealis seeks to maximize the potential of legume crops. Additionally, the company employs proprietary seed coatings to support farmers in addressing the protein deficit and to provide local sourcing solutions for an increasing number of producers in the meat and milk alternatives sector.
AgomAb Therapeutics
Series B in 2021
AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.
Oxular
Venture Round in 2021
Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments aimed at addressing various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technologies designed to enhance the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular aims to improve patient outcomes, reduce side effects, and decrease the frequency of treatments required. The company is committed to transforming the landscape of retinal therapeutics and providing life-changing solutions for patients facing unmet medical needs.
Aphea.Bio
Series B in 2020
Aphea.Bio is a company focused on developing next-generation biopesticides and biostimulants derived from natural microorganisms. Its biopesticides serve as an alternative to conventional chemical pesticides, addressing the increasing pressure on synthetic chemical use in agriculture. Additionally, the company creates biostimulants that enhance crop growth by improving the uptake of nutrients from the soil. Aphea.Bio's products aim to sustainably increase crop yields and health, specifically targeting crops such as maize and wheat. By utilizing proprietary technologies, the company accelerates the discovery of innovative biocontrol and biostimulant solutions, enabling farmers to manage pests, diseases, and fertilizer application more effectively.
Animab is a biotechnology company focused on enhancing livestock health through innovative solutions. The company specializes in developing monoclonal antibodies that mimic secretory IgA, a natural antibody found in colostrum and milk, to protect nursing animals. Animab's technology targets specific intestinal pathogens in livestock, particularly during the critical post-weaning stage for piglets, without disrupting the healthy microbiome. This approach aims to improve animal health, reduce costs, and promote sustainability in livestock production.
Syndesi Therapeutics
Series A in 2020
Syndesi Therapeutics SA is a biotechnology company based in Louvain-la-Neuve, Belgium, founded in 2018. The company specializes in developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that enables communication between neurons in the brain. This innovative approach aims to address cognitive impairments associated with conditions such as Alzheimer’s Disease. Syndesi Therapeutics holds an exclusive license for its platform technology from UCB, a leader in SV2A research, positioning the company to advance therapeutic options for patients suffering from cognitive disorders.
Biodol Therapeutics
Series A in 2020
Biodol Therapeutics SAS is a biotechnology company based in Clapiers, France, established in 2015. The company focuses on developing innovative compounds for the treatment of chronic pain, specifically targeting the Receptor Tyrosine Kinase (RTK) FLT3, which plays a critical role in triggering and sustaining chronic neuropathic pain. Biodol Therapeutics' research indicates that inhibiting FLT3 can enhance the effectiveness of opioids, potentially reducing their risk of addiction and contributing to solutions for the opioid crisis. By creating extracellular inhibitors of the FLT3 receptor, the company aims to alleviate pain hypersensitivity, allodynia, and spontaneous pain while preserving normal nervous system function. Through academic partnerships, Biodol Therapeutics continues to advance its understanding of pain mechanisms and develop its proprietary therapeutic approaches.
ExeVir Bio
Series A in 2020
ExeVir Bio BV is a Belgian biotechnology company founded in 2020 and headquartered in Zwijnaarde. The company specializes in developing single-domain antibody-based therapies aimed at preventing viral infections. Utilizing a llama-derived antibody technology platform, ExeVir Bio focuses on creating robust antiviral treatments, particularly targeting coronaviruses. One of its key products, VHH72-FC, binds to a conserved region of the SARS-CoV-2 spike protein, which is crucial for the virus's entry into human cells. The company has established a rapid response platform for antivirals, allowing for a quick adaptation to emerging health threats through a streamlined process for generating drug candidates. Their protein-based therapeutics are designed to be stable, cost-effective, and accessible on a global scale, addressing significant public health challenges posed by viral infections.
Orionis Biosciences
Series B in 2020
Orionis Biosciences is an early-stage biotechnology company dedicated to drug discovery and development, primarily targeting oncology and immunotherapies for diseases with significant unmet medical needs. Based in Waltham, Massachusetts, with additional research facilities in Ghent, Belgium, the company utilizes innovative technologies to create conditionally active drug modalities. Orionis employs mechanisms of molecular proximity and cooperativity to enhance drug potency and precision, leading to a diverse pipeline of drug candidates. These efforts include the development of small molecules that engage both adaptive and innate immune systems, paving the way for effective single-agent therapies for cancer and other life-threatening conditions. The company is supported by a team of experienced professionals and maintains strategic collaborations with leading research institutions, such as VIB in Belgium.
RootWave is a United Kingdom-based company that specializes in developing and distributing innovative machinery designed to eliminate weeds in agricultural settings. Founded in 2012 and headquartered in Kineton, the company offers a range of products, including hand weeders for growers, gardeners, and groundskeepers, as well as automated solutions that utilize visual recognition technology to target weeds in arable crops. RootWave's electric shock technology effectively kills unwanted plants from the root upwards without the use of chemicals, providing a sustainable and economical alternative to traditional herbicides. The company's products are distributed through various channels in regions such as France, Australasia, Ireland, and South Korea.
Augustine Therapeutics
Seed Round in 2019
Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.
Confo Therapeutics
Series A in 2019
Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.
AgomAb Therapeutics
Series A in 2019
AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.
Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.
Coave Therapeutics
Series B in 2018
Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.
Syndesi Therapeutics
Series A in 2018
Syndesi Therapeutics SA is a biotechnology company based in Louvain-la-Neuve, Belgium, founded in 2018. The company specializes in developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that enables communication between neurons in the brain. This innovative approach aims to address cognitive impairments associated with conditions such as Alzheimer’s Disease. Syndesi Therapeutics holds an exclusive license for its platform technology from UCB, a leader in SV2A research, positioning the company to advance therapeutic options for patients suffering from cognitive disorders.
Aphea.Bio
Series A in 2017
Aphea.Bio is a company focused on developing next-generation biopesticides and biostimulants derived from natural microorganisms. Its biopesticides serve as an alternative to conventional chemical pesticides, addressing the increasing pressure on synthetic chemical use in agriculture. Additionally, the company creates biostimulants that enhance crop growth by improving the uptake of nutrients from the soil. Aphea.Bio's products aim to sustainably increase crop yields and health, specifically targeting crops such as maize and wheat. By utilizing proprietary technologies, the company accelerates the discovery of innovative biocontrol and biostimulant solutions, enabling farmers to manage pests, diseases, and fertilizer application more effectively.
Octimet Oncology
Series A in 2017
OCTIMET Oncology NV is a biotechnology company based in Beerse, Belgium, that specializes in developing MET kinase inhibitors for cancer treatment. Founded in 2016, the company focuses on advancing discovery-stage molecules, including cMET inhibitors and other selective anti-tumor agents. OCTIMET employs innovative strategies for patient selection and pharmacodynamic biomarkers to enhance the clinical development of its therapies. By utilizing biomarker-defined intelligent patient selection, OCTIMET aims to provide differentiated treatment options for patients with solid tumors, thereby improving outcomes within existing treatment paradigms.
Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments aimed at addressing various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technologies designed to enhance the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular aims to improve patient outcomes, reduce side effects, and decrease the frequency of treatments required. The company is committed to transforming the landscape of retinal therapeutics and providing life-changing solutions for patients facing unmet medical needs.
Orionis Biosciences
Series A in 2016
Orionis Biosciences is an early-stage biotechnology company dedicated to drug discovery and development, primarily targeting oncology and immunotherapies for diseases with significant unmet medical needs. Based in Waltham, Massachusetts, with additional research facilities in Ghent, Belgium, the company utilizes innovative technologies to create conditionally active drug modalities. Orionis employs mechanisms of molecular proximity and cooperativity to enhance drug potency and precision, leading to a diverse pipeline of drug candidates. These efforts include the development of small molecules that engage both adaptive and innate immune systems, paving the way for effective single-agent therapies for cancer and other life-threatening conditions. The company is supported by a team of experienced professionals and maintains strategic collaborations with leading research institutions, such as VIB in Belgium.
Confo Therapeutics
Venture Round in 2016
Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.